Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-ECLIPSE: Enfortumab Vedotin + Pembrolizumab in Urothelial Carcinoma Prior to Surgery
NCT05239624Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin and pembrolizumab in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Pathologic Complete Response Rate at 2 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05239624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239624.